YARROW Trademark

Trademark Overview


On Wednesday, August 25, 2021, a trademark application was filed for YARROW with the United States Patent and Trademark Office. The USPTO has given the YARROW trademark a serial number of 90902340. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Wednesday, June 12, 2024. This trademark is owned by Yarrow Biotechnology, Inc.. The YARROW trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical products and preparations for central nervous system and ophthalmic diseases and disorders; genetic therapy products and preparations, namely, oligonucleotide therapies for central nervous system and ophthalmic diseases and disorders; biological products and preparations, namely, monoclonal antibodies, multi-specific antibodies, protein therapeutics, and cell-based therapeutics for central nervous system and ophthalmic diseases and disorders for medical use; all of the foregoing excluding dietary and nutritional supplements

Scientific research and development; research and development in the pharmaceutical and biotechnology fields; research and development of technology in the fields of disease treatment and gene therapy; technological assessment, research, and development of medical devices, pharmaceutical products, gene therapies, and treatment modalities for a range of diseases
yarrow

General Information


Serial Number90902340
Word MarkYARROW
Filing DateWednesday, August 25, 2021
Status731 - SECOND EXTENSION - GRANTED
Status DateWednesday, June 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 24, 2023

Trademark Statements


Goods and ServicesPharmaceutical products and preparations for central nervous system and ophthalmic diseases and disorders; genetic therapy products and preparations, namely, oligonucleotide therapies for central nervous system and ophthalmic diseases and disorders; biological products and preparations, namely, monoclonal antibodies, multi-specific antibodies, protein therapeutics, and cell-based therapeutics for central nervous system and ophthalmic diseases and disorders for medical use; all of the foregoing excluding dietary and nutritional supplements
Goods and ServicesScientific research and development; research and development in the pharmaceutical and biotechnology fields; research and development of technology in the fields of disease treatment and gene therapy; technological assessment, research, and development of medical devices, pharmaceutical products, gene therapies, and treatment modalities for a range of diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 12, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, October 12, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameYarrow Biotechnology, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10014

Party NameYarrow Biotechnology, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10014

Trademark Events


Event DateEvent Description
Saturday, August 28, 2021NEW APPLICATION ENTERED
Tuesday, October 12, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, May 27, 2022ASSIGNED TO EXAMINER
Friday, May 27, 2022NON-FINAL ACTION WRITTEN
Friday, May 27, 2022NON-FINAL ACTION E-MAILED
Friday, May 27, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 22, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, May 27, 2022NON-FINAL ACTION WRITTEN
Friday, May 27, 2022NON-FINAL ACTION E-MAILED
Friday, May 27, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 22, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, November 22, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 20, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 24, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, January 4, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 24, 2023PUBLISHED FOR OPPOSITION
Wednesday, February 1, 2023OPPOSITION INSTITUTED NO. 999999
Wednesday, February 1, 2023OPPOSITION PAPERS RECEIVED AT TTAB
Friday, July 7, 2023OPPOSITION TERMINATED NO. 999999
Friday, July 7, 2023OPPOSITION DISMISSED NO. 999999
Friday, July 7, 2023TTAB RELEASE CASE TO TRADEMARKS
Tuesday, August 22, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, February 8, 2024SOU TEAS EXTENSION RECEIVED
Thursday, February 8, 2024SOU EXTENSION 1 GRANTED
Friday, February 9, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 12, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, June 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 12, 2024SOU EXTENSION 2 FILED
Wednesday, June 12, 2024SOU EXTENSION 2 GRANTED
Thursday, February 8, 2024SOU EXTENSION 1 FILED